A significant portion of disease-relevant proteins remain “undruggable” by traditional therapeutic approaches, representing a major hurdle in drug discovery. Targeted protein degradation (TPD) is rapidly advancing as a strategy to overcome this challenge, enabling the selective elimination of previously inaccessible proteins. A growing array of modalities—including heterobifunctional degraders, molecular glues, antibody-based degraders, and lysosome-targeting agents—are being developed to exploit this mechanism.
This session will explore how to identify and validate targets for protein degraders in autoimmune disease and cancer. We will discuss how to understand the biological roles and pathways of these targets, assess preclinical and mechanistic data, evaluate early safety signals, and monitor competitive landscape in this fast-evolving space. With access to integrated, up-to-date intelligence, researchers can stay informed and make confident decisions in this dynamic and promising field.